302 related articles for article (PubMed ID: 28624108)
1. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation.
De Simone P; Carrai P; Coletti L; Ghinolfi D; Petruccelli S; Filipponi F
Best Pract Res Clin Gastroenterol; 2017 Apr; 31(2):199-209. PubMed ID: 28624108
[TBL] [Abstract][Full Text] [Related]
2. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
[TBL] [Abstract][Full Text] [Related]
3. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis.
Tejedor-Tejada J; Alonso-Martín C; Almohalla-Álvarez C; Valenzuela EF; Muñoz RN; Delgado LS; Martín CM; Sánchez-Martín F; García-Pajares F; Sánchez-Antolín G
Transplant Proc; 2020 Jun; 52(5):1507-1510. PubMed ID: 32213292
[TBL] [Abstract][Full Text] [Related]
5. Impact of 3 Major Maintenance Immunosuppressive Protocols on Long-term Clinical Outcomes: Result of a Large Multicenter Italian Cohort Study Including 5635 Renal Transplant Recipients.
Caletti C; Manuel Ferraro P; Corvo A; Tessari G; Sandrini S; Capelli I; Minetti E; Gesualdo L; Girolomoni G; Boschiero L; Lupo A; Zaza G
Transplant Proc; 2019; 51(1):136-139. PubMed ID: 30655148
[TBL] [Abstract][Full Text] [Related]
6. Calcineurin inhibitors in liver transplantation - still champions or threatened by serious competitors?
Beckebaum S; Cicinnati VR; Radtke A; Kabar I
Liver Int; 2013 May; 33(5):656-65. PubMed ID: 23442173
[TBL] [Abstract][Full Text] [Related]
7. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE
PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
[TBL] [Abstract][Full Text] [Related]
8. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
10. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
[TBL] [Abstract][Full Text] [Related]
11. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade.
Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C
Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546
[TBL] [Abstract][Full Text] [Related]
12. Effect of Immunosuppressive Treatment on Carotid Atherosclerosis in Renal Transplant Recipients.
Szymczak M; Kluz J; Małecki R; Wątorek E; Obremska M; Głuszek M; Klinger M; Boratyńska M
Transplant Proc; 2016 Jun; 48(5):1626-9. PubMed ID: 27496459
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients.
Walsh C; Barkun J; Tchervenkov J; Deschenes M; Ghali P; Wong P; Chaudhury P; Paraskevas S; Metrakos P; Cantarovich M
Transplantation; 2013 Feb; 95(3):495-500. PubMed ID: 23296149
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.
Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Gotthardt D; Loss M; Ladenburger S; Wimmer P; Dworak M; Schlitt HJ
Clin Transplant; 2016 Jun; 30(6):741-8. PubMed ID: 27160359
[TBL] [Abstract][Full Text] [Related]
15. mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis.
Zhang G; Duan B; Li G
Clin Transplant; 2022 Dec; 36(12):e14823. PubMed ID: 36124430
[TBL] [Abstract][Full Text] [Related]
16. Neurological complications after liver transplantation as a consequence of immunosuppression: univariate and multivariate analysis of risk factors.
Rompianesi G; Montalti R; Cautero N; De Ruvo N; Stafford A; Bronzoni C; Ballarin R; De Pietri L; Di Benedetto F; Gerunda GE
Transpl Int; 2015 Jul; 28(7):864-9. PubMed ID: 25790037
[TBL] [Abstract][Full Text] [Related]
17. Current immunosuppressive approaches in liver transplantation.
Iacob S; Cicinnati VR; Beckebaum S
Panminerva Med; 2009 Dec; 51(4):215-25. PubMed ID: 20195232
[TBL] [Abstract][Full Text] [Related]
18. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
Nelson LM; Andreassen AK; Andersson B; Gude E; Eiskjær H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
Transplantation; 2017 Nov; 101(11):2793-2800. PubMed ID: 28230646
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]